Lv7
5000 积分 2022-08-11 加入
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
5天前
已完结
Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index
24天前
已完结
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
2个月前
已完结
Overcoming therapy resistance in EGFR-mutant lung cancer
3个月前
已完结
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
4个月前
已完结
Annual review of PROTAC degraders as anticancer agents in 2022
4个月前
已完结
Discovering the anticancer potential of non-oncology drugs by systematic viability profiling
7个月前
已完结
皖公网安备34019202002308
